Kornimate/medical-research-clean huggingface dataset:
tofatib treatment for igg4-related disease

Conditions: IgG4-related Disease

Summary: compared with cyclophosphamide, the efficacy and safety of tofacitinib in the treatment of active igg4-related diseases were evaluated.

this study is a prospective, single center, non randomized, controlled, open label clinical observation study to evaluate the efficacy and safety of tropitib versus cyclophosphamide in inducing remission in igg4-rd patients. 2) investigators observe the diagnosis and treatment of igg4-rd patients, and only provide patients with clinically appropriate diagnosis and treatment proposals. it does not interfere with the choice of treatment plan for patients with the study drug of tropib or cyclophosphamide. if the patient chooses the hormone combined with tofatib or the hormone combined with cyclophosphamide as the main treatment drug, and at the same time meets the inclusion and exclusion criteria of this study, the patient can be included in this clinical observation study and become a subject. the experimental group was treated with glucocorticoid combined with tofatib, and the control group was treated with glucocorticoid combined with cyclophosphamide. it is planned that 20 people in each group will be treated for 6 months. after the study, the number of subjects in each group shall be at least 20 according to the actual situation. in the final statistical analysis, ensure that the sample size of the two groups participating in the statistical analysis is controlled at about 1:1. 3) the primary end point of this study was to compare the remission rate of the two groups after treatment; the secondary end point was to compare the response rate, recurrence rate and adverse event rate of the two groups after treatment.

Eligibility criteria:
inclusion criteria: * it meets the 2019 acr/eular classification diagnostic criteria for igg4 related diseases, and is an active igg4-rd, defined as an igg4-rd ri score ≥ 3 points when screening exclusion criteria: * 1. igg4 related diseases endangering organ function or life; 2. only mikulicz disease, no other internal organs involved; 3. people with history of thrombotic disease or high risk of thrombosis; 4. have a history of malignant tumor; 5. active infection; 6. pregnant or lactating women;
pnf techniques versus stabilization exercises of trapezius muscle pnf techniques verus stabilization exercises of trapezius muscle

Conditions: Neck Pain

Summary: this project will compare the effects of proprioceptive neuromuscular facilitation stretching and stabilization of upper trapezius on pain, range of motion and functional disability in mobile phone user with mobile phone-induced neck pain. the population sample will be 50 divided randomly into two groups by concealed envelop method. then i will collect data from the social security hospital physiotherapy department, lahore. group a was given stretching exercises and group b was given stabilization exercises (25 stretchings and 25stabilization). ndi and nprs were used as an outcome measure to quantify the upper trapezius on pain, range of motion, and functional disability with non-specific neck pain.

this project will compare the effects of proprioceptive neuromuscular facilitation stretching and stabilization of upper trapezius on pain, range of motion and functional disability in mobile phone user with mobile phone-induced neck pain. the population sample will be 50 divided randomly into two groups by concealed envelop method. then i will collect data from the social security hospital physiotherapy department, lahore. group a was given stretching exercises and group b was given stabilization exercises (25 stretchings and 25stabilization). ndi and nprs were used as an outcome measure to quantify the upper trapezius on pain, range of motion, and functional disability with non-specific neck pain. single blinding of accessor was done at the time of recording of outcome measures pre and post-treatment baseline was 4th week and 8th week. eighty female participants and twenty male participants in each group. the duration was 9 months. the 18-30 years age range of both males and females were considered. there was not any statistically significant difference between the two groups as p \> 0.05. but within-group changes show that there was a significant change in baseline, 4th week, and 8th-week readings for ndi, nprs, and rom with p \< 0.05.

Eligibility criteria:
inclusion criteria * male and female, age range 18-30years with non-specific neck pain. * permanently mobile users spent more than 8 hours per day using their mobiles * participants are willing to participate in the research. * having constant or frequent neck pain of more than 4weeks duration. exclusion criteria: * specific disorders of the cervical spine, such as disc prolapse, spinal stenosis, postoperative conditions in the neck and shoulder areas. * history of severe trauma, instability, spasmodic torticollis, migraine (frequency more than twice per month). * peripheral nerve entrapment, fibromyalgia, hypermobility syndrome, shoulder diseases (tendonitis, bursitis, capsulitis). * inflammatory rheumatic diseases, severe psychiatric illness, and other diseases that prevent physical loading, pregnancy, and other on-going therapies.
oral health care in stroke patients in tertiary care hospital

Conditions: Gingivitis; Periodontitis; Dental Hygiene

Summary: to investigate oral care provision in stroke care settings in pakistan. stroke can have adverse effects on oral care and health. little is known about current oral care practices in stroke care settings.

for a variety of related reasons, stroke can adversely affect oral care. physical impairment, coordination, sensory or cognitive deficits may accompany a stroke and can impact on independent oral care. post-stroke alterations in facial muscle mass or movement and sensory problems may result in poorly controlled dentures. dysphagia can contribute to oral care concerns in a number of ways. oral intake of fluids may be restricted to reduce the risk of aspiration pneumonia, which in turn can contribute to xerostomia. nutritional supplements, often prescribed, are high in sugar and may predispose to caries. furthermore, because of swallowing impairment, pharmacological interventions are often administered in syrup consistency, which is sugar-based, and may also predispose to caries. reduced swallowing ability causes ineffective clearance of bacteria and debris from the mouth leading to caries and infection. some pharmacological interventions in stroke care are known to have oral side effects. oxygen therapy frequently administered in acute stroke management is known to cause mucosal drying and blistering. the absence of normal chewing patterns as a result of pain, physical or sensory impairment can also reduce salivary function. xerostomia also causes pain, taste disturbance, chewing, and swallowing difficulties. speech and denture retention is also affected by inadequate saliva. this, in turn, increases plaque formation, predisposes to opportunistic oral infections, periodontal disease, and caries, conditions which place the individual at greater risk of pain, tooth loss and tooth substance loss. chronic periodontal infection is currently being tentatively linked with the incidence of the stroke itself, while others have demonstrated a relationship with other systemic diseases including pneumonia and cardiovascular disease. healthcare-led oral care is a complex intervention and comprises a number of elements. these include assessment, accessing further assistance as required, and the use of appropriate equipment and cleaning methods. knowledge is also required to assess and apply oral care at an individual level.

Eligibility criteria:
inclusion criteria: * patient with diagnosed case of stroke * both gender will be included. exclusion criteria: * patients with a known case of bleeding diathesis. * patient not willing to participate * patient with known head and neck cancer and oral pathology
increasing breast, cervical, and colorectal cancer screening and hpv vaccination among underserved texans

Conditions: Cancer Prevention

Summary: this study involves a partnership between uthealth school of public health and the texas 2-1-1 service, which is a helpline connecting low-income and minority callers with a number of needed services. the purpose of this study is to evaluate the effectiveness of a prevention program in which a phone navigator intervention designed to connect 2-1-1 helpline callers to evidence-based screening and prevention services including mammography, pap test screening, colorectal cancer screening, and hpv vaccination.


Eligibility criteria:
inclusion criteria: * callers to 2-1-1 * consents to participate, * english or spanish speaking * not in a crisis (e.g., disaster-related 2-1-1 call or personal crisis) exclusion criteria: * not english or spanish speaking * in crisis (e.g., disaster-related call or personal crisis) * calling on behalf of another client and not for self
comfort study: a crossover study of neorecormon (epoetin beta) and darbepoetin alfa in patients with renal anemia.

Conditions: Anemia

Summary: this study will assess the comfort of subcutaneous injections of neorecormon and darbepoetin alfa (aranesp) in patients with renal anemia. eligible patients will be randomized to receive comparable subcutaneous injections of either darbepoetin alfa (30 micrograms) or neorecormon (6000iu). they will then be crossed over to the alternative treatment arm for further treatment. after each injection pain will be assessed using the visual analogue scale (vas) and 6-point verbal rating scale (vrs), and patient preference will be assessed. the anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>18 years of age; * patients with renal anemia or post-transplant anemia. exclusion criteria: * poorly controlled hypertension; * known hypersensitivity to neorecormon or darbepoetin alfa.
application of cfdna methylation detection in auxiliary diagnosis of breast cancer

Conditions: Breast Cancer Screening

Summary: the purpose of this study is to construct an auxiliary diagnostic model for breast cancer by methylation markers. the study will collect blood and tissue samples from participants with breast cancer and benign disease for whole-genome methylation sequencing. it will screen methylation markers and develop a methylation auxiliary diagnosis model to distinguish between breast cancer and non-cancer.


Eligibility criteria:
inclusion criteria for all the participants: * with confirmed pathological diagnosis and molecular subtyping results * ability to provide a written informed consent exclusion criteria for cancer arm participants: * patients with a history of or currently suffering from other malignancies * pregnant or planning to become pregnant female patients * patients who have received cancer treatment, including surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy, before blood draw * patients with a history of blood transfusion within the past month * patients with a known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation * patients with persistent fever or undergoing anti-inflammatory treatment within 14 days before blood draw * any other conditions that the researcher deems may make the patient unsuitable for inclusion in the study or may interfere with the completion of the study * patients in poor physical condition who are not suitable for blood draw * patients who cannot provide informed consent or refuse blood draw exclusion criteria for benign diseases arm participants: * history of malignancies * current malignancies or precancerous lesions
effect of intermittent normobaric hypoxia on executive functions

Conditions: Executive Function (Cognition); Normobaric Hypoxia

Summary: the main objective of this study was to analyze the effects of an intermittent normobaric hypoxia session on executive functions assessed with different cognitive tests given to healthy young subjects. twenty-seven healthy volunteers were divided into an experimental group (eg; n=13) and a control group (cg; n=14). the eg performed the 'odd one out', 'double trouble' and 'monkey ladder' tests before and after the hypoxia tolerance session (12%, 4400 m) with the ialtitude simulator. the cg completed the same tests without hypoxia exposure.

the main objective of this study will be to analyze the effects of an intermittent normobaric hypoxia session on executive functions, assessed using different cognitive tests administered to healthy young subjects. a total of 27 healthy volunteers will be divided into two groups: an experimental group (eg; n=13) and a control group (cg; n=14). the experimental group will perform the 'odd one out', 'double trouble', and 'monkey ladder' tests immediately before and after a hypoxia tolerance session (12% oxygen, equivalent to 4400 meters) using the ialtitude simulator. the control group will complete the same tests under normoxic conditions, without exposure to hypoxia. the primary outcomes will include changes in cognitive performance scores in the administered tests. the experimental group is expected to show improvements in the double trouble test scores following hypoxia exposure. the control group may also show changes in the double trouble and odd one out tests between the pre- and post-tests. secondary outcomes will include physiological variables such as oxygen saturation (sao₂) and heart rate (hr), which will be monitored during the hypoxia session in the eg. statistically significant changes in sao₂ and hr are anticipated as a result of the hypoxic exposure. this study aims to determine whether a single session of intermittent normobaric hypoxia can lead to selective improvements in executive functions, particularly sustained attention, without negatively affecting other cognitive domains.

Eligibility criteria:
inclusion criteria: * young people aged between 18 and 40 years old exclusion criteria: * pregnancy * prior experience in hypoxia training * previous experience in executive function tests * personal or family history of cardiovascular diseases or chronic conditions * diagnosed cardiac disorders.
homeopathic ear drops for otitis media study

Conditions: Otitis Media

Summary: the purpose of this study is to determine if a commercially available homeopathic ear drop preparation is effective in reducing symptoms in children 6 months - 11 years old with acute otitis media in whom the health care provider has recommended that antibiotics not be immediately administered. a total of 150 study patients with otitis media will be randomized to receive homeopathic ear drops, or no ear drops, in addition to receiving standard care. it is postulated that children using the ear drops will have more rapid resolution of symptoms and need fewer antibiotics than those randomized to not receive the ear drops.


Eligibility criteria:
inclusion criteria: * age 6 months - 11 years old * diagnosed with otitis media by clinician at participating clinic * clinician determines that a "watch and wait" antibiotic prescription treatment plan is optimal management exclusion criteria: * antibiotic treatment during past 7 days * homeopathic treatment within past 30 days * history of serious chronic illness (e.g. diabetes, autoimmune disease, cystic fibrosis * perforated tympanic membrane * immediate antibiotic treatment plan decided by examining clinician

Keywords: otitis media children homeopathy
ganglionated plexi ablation vs renal denervation in patients undergoing pulmonary vein isolation

Conditions: Atrial Fibrillation; Hypertension

Summary: the investigators have conducted a prospective, double-blind, randomized study to assess the comparative safety and efficacy of two different strategies, pvi plus renal denervation (rd) versus pvi plus gp ablation, in patients with atrial fibrillation. results were assessed after follow-up of at least 1 year with the use of an implanted monitoring device (imd).


Eligibility criteria:
inclusion criteria: * symptomatic drug-refractory af (with history of failure of ≥ 2 class i or iii antiarrhythmic drugs) in patients referred for catheter ablation of af * paf with ≥1 monthly episodes or persaf in patients who had already undergone ≥3 electrical cardioversions. paf was defined as episodes lasting less than 7 days with spontaneous termination. persaf was defined as lasting more than 7 days before being terminated pharmacologically or by electrical cardioversion. * history of significant hypertension (defined as sbp ≥ 160 mmhg and/or dbp ≥ 100 mmhg), receiving treatment with at least one antihypertensive medication * a glomerular filtration rate ≥45 ml/min/1⋅73 m2, with modification of diet using a renal disease formula exclusion criteria: * previous atrial fibrillation ablation * type 1 of diabetes mellitus * structural heart disease * secondary cause of atrial hypertension * severe renal artery stenosis or renal arteries abnormalities * previous operations on renal arteries * pregnancy * previous heart, kidney, liver, or lung transplantation * unwillingness of participant
effects of a psycho-corporal training on postural and cognitive dual-task performances in patients with schizophrenia

Conditions: Schizophrenia

Summary: beside these well-known symptoms (positive symptoms (such as delirium and delusions), negative symptoms (such as affective flattening and impoverishment of speech), disorganized behavior, patients with schizophrenia show different kinds of cognitive alterations and motor abnormalities. in schizophrenia, postural impairment could increase the attentional cost of daily motor tasks, leading to a lack of attentional resources, essential to achieve complex cognitive tasks. the intrication of cognitive and postural processings (both impaired in schizophrenia) can be explored by using of a dual-task paradigm.

this study assesses a psycho-corporal training (8 weeks psycho-corporal training) benefits on both postural (increased automation of balance control) and cognitive processings (smaller impact of the dual-task condition on attentional performances) in population of patients suffering from schizophrenia.

Eligibility criteria:
inclusion criteria: * a dsm-iv (diagnostic and statistical manual of mental disorders) diagnosis of schizophrenia (men or women) * men or woman aged 18-55 * patients with no change in antipsychotic medication and clinical status within four weeks prior to the study * affiliates or entitled to a social security scheme * have given their informed consent before participating in the study. exclusion criteria: * intelligence quotient below 70 (score pm38) * history of head trauma, neurological disease or not stabilized serious physical illness * disorders related to the use of a psychoactive substance, as defined by the dsm-iv (abuse, dependence or withdrawal) within 6 months.

Keywords: schizophrenia postural cognitive task
study to assess safety, tolerability and clinical activity of bgb-290 in combination with temozolomide (tmz) in participants with locally advanced or metastatic solid tumors

Conditions: Locally Advanced or Metastatic Solid Tumors

Summary: the primary objective of this study was to determine the safety and tolerability of pamiparib, the maximum tolerated dose (mtd) or maximum administered dose (mad) for pamiparib combined with tmz, to select the recommended phase 2 dose (rp2d) and schedule of pamiparib in combination with tmz, and to determine the antitumor activity of pamiparib in combination with tmz.


Eligibility criteria:
key inclusion criteria: 1. age ≥18 years old with advanced or metastatic stage solid tumors 2. eastern cooperative oncology group (ecog) status ≤ 1 3. have disease either evaluable (dose-escalation cohort) or measurable (dose-escalation and -expansion cohorts) per recist v1.1, except for prostate cancer participants 4. agree to provide archival tumor tissue 5. additional inclusion criteria for dose expansion cohorts: * participants with homologous recombination deficiency (hrd+) or known brca mutant ovarian cancer previously received at least one line of platinum-containing therapy in the advanced or metastatic setting and no progression or recurrent disease within 6 months from last platinum-containing regimen. * participants with hrd+ or known brca mutant triple-negative breast cancer up to one prior platinum-containing treatment in any treatment setting and up to 3 prior lines of therapy in the advanced or metastatic setting * participants with hrd+ or known brca mutant prostate cancer chemotherapy-naïve or previously received up to two taxane-based chemotherapy regimens, with documented prostate cancer progression * participants with small cell lung cancer and gastric cancer, previously received ≤ 2 prior lines of therapy * other hrd+ solid tumors of multiple indications key exclusion criteria: all participants 1. prior treatment with a poly adenosine diphosphate-ribose polymerase (parp) inhibitor. 2. refractory to platinum-based therapy (dose-expansion cohort). note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: ovarian cancer triple negative breast cancer small cell lung cancer gastric cancer temozolomide bgb-290 antineoplastic agents alkylating, alkylating agents, poly (adp-ribose) polymerase inhibitors enzyme inhibitors head and neck cancer esophageal cancer soft tissue sarcoma non small cell lung cancer pamiparib
mosaic - multicenter international study of oxaliplatin/ 5fu-lv in the adjuvant treatment of colon cancer

Conditions: Colonic Neoplasms

Summary: to evaluate the folfox regimen versus lv5fu2 in the adjuvant treatment of stage ii and iii colon cancer. primary objective: disease free survival (dfs) secondary objective: overall survival (os), safety (including long term toxicity)


Eligibility criteria:
main selection criteria: * histologically proven stage dukes " b2 " (stage ii: t3-t4 n0 m0) and " c " (stage iii: any t n1-2 m0) colon carcinoma. the inferior pole of the tumor must be above the peritoneal reflection (\> 15 cm from the anal margin)· * complete resection of the primary tumor without gross or microscopic evidence of residual disease * treatment within 7 weeks following surgery * age 18-75 years old * ecog ps £ 2 * no prior chemo, immuno or radiotherapy

Keywords: oxaliplatin chemotherapy,adjuvant colonic neoplasms
non-interventional study (nis) in patients with restless legs syndrome in daily practise

Conditions: Idiopathic Restless Legs Syndrome

Summary: this non-interventional observational study is designed to gain data for neupro® in restless legs syndrome (rls) under real life conditions in line with the summary of product characteristics (smpc) related to effectiveness, tolerability and switching practice from other dopaminergic drugs as well as titration schemes.

there is a total of 64 subjects recorded as having discontinued due to adverse events. documentation of visit 2 and visit 3, where the reason for discontinuation was documented, was not available for all subjects. from the documentation on the adverse events page in the case report form, it is known that 100 subjects discontinued due to adverse events. the last observation carried forward (locf) method was utilized for all outcomes.

Eligibility criteria:
inclusion criteria: * it was recommended that the patient's treatment was in accordance with the local marketing authorization (ma) for neupro® * the patient must have a diagnosis of moderate to severe idiopathic rls * the patient is considered reliable and capable of adhering to the visit schedule or medication administration according to the judgment of the investigator * the decision to prescribe the drug has been made by the physician independently of his/her decision to include the patient in the study * subject is informed and given ample time and opportunity to think about his/her participation in the study and has given written informed data consent exclusion criteria: * hypersensitivity to the active substance or to any of the excipients * magnetic resonance imaging or cardioversion (see smpc)

Keywords: rotigotine neupro® restless legs syndrome